Expanded manufacturing EVA Pharma operates four state-of-the-art manufacturing facilities with the capacity to produce over one million healthcare products daily, indicating strong scale and potential for large-volume supply partnerships across Africa and beyond.

Oncology and immunotherapy Recent and upcoming collaborations with BeiGene and plans to develop immunotherapy hematology and oncology treatments signal a strategic opportunity to position your products in EVA Pharma’s expanding cancer portfolio and high-value therapy areas.

RNA and vaccine capacity Investments in mRNA research and RNA-based vaccine production through partnerships with DNA Script, Quantoom, and Porton Advanced point to a readiness for advanced biologics manufacturing, presenting a pathway for high-margin biologics and RNA therapeutics collaborations.

Regional access, global reach With presence in over 60 countries and a focus on sustainable access across Africa and the Middle East, there is a strong channel for distribution partnerships, contract manufacturing, and technology transfer agreements to accelerate market reach.

Strategic partnerships Active MOUs and collaborations across immunization, vaccines, and cell therapy ecosystems (PharmaJet, Alameda Group, Porton Advanced, DNA Script) create multiple entry points for co-development, licensing, and commercial deals in high-growth segments.